The US Food and Drug Administration (FDA) has approved an investigational new drug application from Vegenics, a subsidiary of Circadian Technologies, to commence clinical trials of VGX-100 for the treatment cancer patients with solid tumours.
VGX-100 is a human antibody that acts against the human VEGF-C protein.
In animal models, VGX-100 combined with Avastin and chemotherapy has been shown to reduce tumour growth and tumour spread, and improve tumour inhibition.
The Phase I study will investigate VGX-100 in patients with a variety of late-stage cancers.
Circadian Technologies CEO Robert Klupacs said the company expects to start clinical trials before the end of 2011, with results becoming available in the second half of 2012.
The company is also developing VGX-100 for other cancer indications, as well as an agent to treat front-of the-eye diseases.